ADMA Biologics, Inc. (NASDAQ:ADMA) CEO Sells $1,072,000.00 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMAGet Free Report) CEO Adam S. Grossman sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $10.72, for a total value of $1,072,000.00. Following the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at approximately $22,313,412. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

ADMA Biologics Trading Down 1.4 %

Shares of ADMA opened at $10.63 on Monday. The business’s 50-day moving average price is $8.17 and its 200 day moving average price is $6.23. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $2.46 billion, a P/E ratio of -531.50 and a beta of 0.48. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $10.85.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last released its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.03. The business had revenue of $81.90 million for the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The firm’s quarterly revenue was up 43.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.03) earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.35 earnings per share for the current year.

Institutional Trading of ADMA Biologics

Several large investors have recently added to or reduced their stakes in the company. Alberta Investment Management Corp grew its holdings in shares of ADMA Biologics by 32.4% during the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock valued at $2,083,000 after buying an additional 112,831 shares in the last quarter. GSA Capital Partners LLP grew its stake in ADMA Biologics by 87.7% during the 3rd quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 113,184 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of ADMA Biologics by 22.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock valued at $4,313,000 after purchasing an additional 224,696 shares during the period. American Century Companies Inc. lifted its position in shares of ADMA Biologics by 20.8% in the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock worth $17,514,000 after purchasing an additional 840,761 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of ADMA Biologics during the third quarter worth approximately $140,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ADMA has been the topic of a number of research analyst reports. Cantor Fitzgerald lifted their target price on ADMA Biologics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, May 10th. Raymond James lifted their price objective on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Mizuho increased their target price on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Finally, HC Wainwright lifted their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $10.50.

Check Out Our Latest Stock Report on ADMA Biologics

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Recommended Stories

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.